Besides the small molecules, anti-HMGB1 monoclonal antibody (mAb) had been demonstrated to neutralize the released HMGB1, prevent the inflammation cascade, and afford a therapeutic effect in ischemic brain injury, traumatic brain injury, Parkinson’s disease, and SCI [14, 56–59]. The gene discussed is HMGB1; the disease is Parkinson disease.